In this Pharmaceutical Executive video interview, Murray Aitken, Executive Director of the IQVIA Institute for Human Data Science, discusses why no novel active substances have yet been brought to market through AI technology despite increasing investments in the space for drug discovery as shown in IQVIA’s Global Trends in R&D 2024 report.
Hurdles Hindering the Translation of AI-Powered Research into Tangible Clinical Benefits
Estimated read time
1 min read
You May Also Like
Where can I buy Tobacco-Free Nicotine products?
February 27, 2025
Ozempic 用於什麼?
February 26, 2025
Global Launch Strategies in the Current Political Climate
February 19, 2025
More From Author
How much does an Office harassment lawyer cost?
July 2, 2026
What projects has Jack Bodenstein completed?
June 16, 2026

+ There are no comments
Add yours